Evidence map›Paper›PMID 42888204›Full record

ArticleBritish journal of cancer2026

Waiting times and determinants of delay for head and neck cancer in England-a population cohort study using real world data.

Farizeh Jashek-Ahmed, Orouba Almilaji, Thomas E Cowling, David W Hamilton, Kate Walker, Vinidh Paleri

Abstract read
PubMed Publisher
In one paragraph

Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Farizeh Jashek-AhmedInternational Centre for Recurrent Head and Neck Cancer, Royal Marsden Hospital NHS Foundation Trust, London, UK. Farizeh.Jashek-Ahmed1@lshtm.ac.uk.ORCID http://orcid.org/0000-0002-9486-4920
Orouba AlmilajiDepartment of Health Services Research & Policy, Faculty of Public Health and Policy, London School of Hygiene & Tropical Medicine, London, UK.ORCID http://orcid.org/0000-0002-0846-5393
Thomas E CowlingDepartment of Health Services Research & Policy, Faculty of Public Health and Policy, London School of Hygiene & Tropical Medicine, London, UK.
David W HamiltonPopulation Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.
Kate Walker *Department of Health Services Research & Policy, Faculty of Public Health and Policy, London School of Hygiene & Tropical Medicine, London, UK.ORCID http://orcid.org/0000-0001-5392-6323
Vinidh Paleri *International Centre for Recurrent Head and Neck Cancer, Royal Marsden Hospital NHS Foundation Trust, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn Head and Neck Cancer (HNC), even short delays in treatment can worsen prognosis. We used real-world data to quantify waiting times and identify patient, tumour and health service factors associated with treatment delay in England.

methodsUsing linked national datasets (Cancer Registry, Cancer Waiting Times, Hospital Episodes Statistics, Radiotherapy and Chemotherapy), we calculated waiting times from referral to first treatment (surgery or (chemo)radiation) and used multivariable logistic regression models to examine factors associated with delay.

resultsOf 30,506 patients, 43% experienced treatment delay ( > 62 days from referral). Long delays ( > 90 days) affected 11% of patients treated with primary surgery and 20% of those receiving primary (chemo)radiation. Non-urgent referral (30% of patients) was the strongest predictor of long delay (aOR 4.07, CI: 3.54-4.68). Additional risk-factors included initial assessment at non-specialist (spoke) hospitals, non-oropharyngeal cancers, and higher socio-economic deprivation.

conclusionsTreatment delays in HNC are worsening, particularly for patients treated with primary (chemo)radiation. Referral route is the strongest determinant. Interventions should focus on optimising referral pathways, increasing awareness of HNC symptoms among the public and primary care, and acknowledging the different drivers of delay associated with surgery and (chemo)radiation therapy.

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.